At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Eritoran +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of TLR4 on Lipid-Induced Insulin Resistance
The University of Texas Health Science Center at San Antonio·interventional·Posted Dec 22, 2014·Updated Oct 8, 2019
In Brief
A Phase 2 clinical trial evaluating Eritoran and D5W (5% Dextrose in water) for Insulin Sensitivity. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin resistance in lean, normal glucose tolerant (NGT) subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsulin Sensitivity
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionSep 2018
TodayJul 2026
First PostedDec 22, 2014
Enrollment StartJan 1, 2015
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.5 years ago
Interventions
Eritorandrug
Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
D5W (5% Dextrose in water)drug
D5W = 5% Dextrose Water Vehicle